Yongbo Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongbo Luo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lijie Zhou
Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
23 shared publications - Youmiao Zeng
Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
23 shared publications - Yuanhao Liu
Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
23 shared publications - Yiheng Dai
Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
18 shared publications - Ke Chen
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
15 shared publications - Cai Zhang
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
KEY SOURCE TABLE from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Gene sets and corresponding primers mentioned in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKEY SOURCE TABLE from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Gene sets and corresponding primers mentioned in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure and legends from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Supplementary figure and legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure and legends from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Supplementary figure and legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Dysregulation of cholesterol homeostasis occurs in multiple types of tumors and promotes cancer progression. Investigating the specific processes that induce abnormal cholesterol metabolism could identify therapeutic targets to improve cancer treatment. In this investigation, we observed upregulation of 7-dehydrocholesterol reductase (DHCR7), a vital enzyme involved in the synthesis of cholesterol, within bladder cancer tissues in comparison to normal tissues, which was correlated with increased bladder cancer metastasis. Increased expression of DHCR7 in bladder cancer was attributed to decreased mRNA degradation mediated by YTHDF2. Loss or inhibition of DHCR7 reduced bladder cancer cell invasion in vitro and metastasis in vivo. Mechanistically, DHCR7 promoted bladder cancer metastasis by activating the cAMP/protein kinase A/FAK pathway. Specifically, DHCR7 increased cAMP levels by elevating cholesterol content in lipid rafts, thereby facilitating the transduction of signaling pathways mediated by cAMP receptors. DHCR7 additionally enhanced the cAMP signaling pathway by reducing the concentration of 7-dehydrocholesterol and promoting the transcription of the G protein–coupled receptor, namely gastric inhibitory polypeptide receptor. Overall, these findings demonstrate that DHCR7 plays an important role in bladder cancer invasion and metastasis by modulating cholesterol synthesis and cAMP signaling. Furthermore, inhibition of DHCR7 shows promise as a viable therapeutic strategy for suppressing bladder cancer invasion and metastasis.Significance:Inhibiting DHCR7 induces cholesterol metabolism reprogramming and lipid raft remodeling to inactivate the cAMP/protein kinase A/FAK axis and suppress bladder cancer metastasis, indicating the therapeutic potential of targeting DHCR7.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis
Dysregulation of cholesterol homeostasis occurs in multiple types of tumors and promotes cancer progression. Investigating the specific processes that induce abnormal cholesterol metabolism could identify therapeutic targets to improve cancer treatment. In this investigation, we observed upregulation of 7-dehydrocholesterol reductase (DHCR7), a vital enzyme involved in the synthesis of cholesterol, within bladder cancer tissues in comparison to normal tissues, which was correlated with increased bladder cancer metastasis. Increased expression of DHCR7 in bladder cancer was attributed to decreased mRNA degradation mediated by YTHDF2. Loss or inhibition of DHCR7 reduced bladder cancer cell invasion in vitro and metastasis in vivo. Mechanistically, DHCR7 promoted bladder cancer metastasis by activating the cAMP/protein kinase A/FAK pathway. Specifically, DHCR7 increased cAMP levels by elevating cholesterol content in lipid rafts, thereby facilitating the transduction of signaling pathways mediated by cAMP receptors. DHCR7 additionally enhanced the cAMP signaling pathway by reducing the concentration of 7-dehydrocholesterol and promoting the transcription of the G protein–coupled receptor, namely gastric inhibitory polypeptide receptor. Overall, these findings demonstrate that DHCR7 plays an important role in bladder cancer invasion and metastasis by modulating cholesterol synthesis and cAMP signaling. Furthermore, inhibition of DHCR7 shows promise as a viable therapeutic strategy for suppressing bladder cancer invasion and metastasis.Significance:Inhibiting DHCR7 induces cholesterol metabolism reprogramming and lipid raft remodeling to inactivate the cAMP/protein kinase A/FAK axis and suppress bladder cancer metastasis, indicating the therapeutic potential of targeting DHCR7.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Supplementary data related to Figure 1-2
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Supplementary data related to Figure 1-2
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Supplementary data related to Figure 3
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Supplementary data related to Figure 3
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Restoration of MLYCD reversed resistance to ENZ in PCa, related to Figure 7
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Restoration of MLYCD reversed resistance to ENZ in PCa, related to Figure 7
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Restoration of MLYCD expression depleted intracellular malonyl-CoA to repress lipid accumulation and activat PERK mediated endoplasmic reticulum stress signaling pathways
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Restoration of MLYCD expression depleted intracellular malonyl-CoA to repress lipid accumulation and activat PERK mediated endoplasmic reticulum stress signaling pathways
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-4 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
The basic clinical information of the human specimens analyzed in the manuscript
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-4 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
The basic clinical information of the human specimens analyzed in the manuscript
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
MLYCD was downregulated in PCa
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
MLYCD was downregulated in PCa
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Ran K141 malonylation promoted AR nuclear localization, related to Figure 5
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
Ran K141 malonylation promoted AR nuclear localization, related to Figure 5